Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versus the standard of care in HIV-1 infected patients with sustained virological response during HAART [Studio clinico randomizzato di non inferiorita sulla efficacia e sicurezza dell uso di efavirenz/tenofovir/emtricitabina in combinazione fissa (Atripla) somministrato a giorni alterni comparato con lo standard of care in pazienti con infezione da HIV-1 in soppressione virologica sotto HAART].

Trial Profile

Non-inferiority,randomized clinical trial to evaluate the efficacy and the safety of the use of fixed-dose combination efavirenz/tenofovir/emtricitabine (Atripla) administered in alternate days versus the standard of care in HIV-1 infected patients with sustained virological response during HAART [Studio clinico randomizzato di non inferiorita sulla efficacia e sicurezza dell uso di efavirenz/tenofovir/emtricitabina in combinazione fissa (Atripla) somministrato a giorni alterni comparato con lo standard of care in pazienti con infezione da HIV-1 in soppressione virologica sotto HAART].

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary)
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 05 Feb 2019 Status changed from recruiting to completed.
    • 05 Feb 2019 Results published in the AIDS
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top